[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaginal-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaginal-cancers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620786","exploring-the-effects-of-hand-and-foot-exercise-intervention-in-older-adults-with-gynecological-cancer-receiving-chemotherapy-improvement-of-peripheral-neuropathy-and-quality-of-life-100620786",false,"NCT07362147","Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life","Inclusion Criteria:\n\nIndividuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions.\n\nIndividuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy.\n\nIndividuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language.\n\nExclusion Criteria:\n\nSkin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure.\n\nDistal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.","FEMALE","65 Years",{"count":18,"type":19},74,"ESTIMATED","INTERVENTIONAL",[22],"NA","Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.",[25,26,27,28,29,30],"Peripheral Neuropathy","Cervical Cancer","Endometrial Cancer","Ovarian Cancer","Vaginal Cancers","Fallopian Tube Cancers",[32],"hand and foot exercises, chemotherapy, gynecological cancer, peripheral neuropathy, quality of life","NOT_YET_RECRUITING","2026-01-21",{"date":36,"type":37},"2026-01-23","ACTUAL",{"date":39,"type":19},"2026-01-01",{"date":41,"type":19},"2027-11-30",{"name":43,"class":44},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100582756","minimally-invasive-pelvic-exenteration-in-vaginal-or-cervical-cancer-recurrence-100582756","NCT06867445","Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence","MIPEX","Inclusion Criteria:\n\n* Diagnosis of recurrent or persistent vaginal or cervical cancer\n* Proven histological diagnosis of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma\n* Isolated central pelvic recurrence\n* MRI-measured maximum tumor diameter ≤ 50 mm\n* Age \\> 18 years\n* Patients who have signed an approved informed consent form\n* Patients must be suitable for surgery\n* ECOG Performance Status of 0, 1 or 2 (Eastern Cooperative Oncology Group)\n\nExclusion Criteria:\n\n* Para-aortic lymph nodes with a short-axis diameter ≥ 15 mm on MRI scan and\u002For SUV max ≥ 2.5 on PET\u002FCT scan\n* Involvement of lateral pelvic structures (on preoperative imaging or during examination under anaesthesia)\n* Sciatic nerve involvement (at pre-operative imaging or during examination under anaesthesia)\n* Distant metastasis at PET\u002FCT scan\n* Any histological type other than squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma\n* Contraindications to surgery\n* Serious concomitant systemic disorders incompatible with surgery or minimally invasive surgery (at the discretion of the investigator)\n* Women unable to tolerate prolonged lithotomy and steep Trendelenburg positions\n* Women with secondary invasive neoplasm in the last 5 years","18 Years",{"count":55,"type":19},64,[22],"The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.",[59,29],"Cervical Cancers",[61,62,63,64,65],"cervical cancer","vaginal cancer","minimally invasive surgery","pelvic exenteration","gynecologic oncology","RECRUITING","2025-07-11",{"date":69,"type":37},"2025-07-17",{"date":71,"type":37},"2025-07-07",{"date":73,"type":19},"2031-03-01",{"name":75,"class":76},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER"]